Vitamin D deficiency. Avitaminosis D
Conditions
Interventions
Intervention 1: Control group C: Subjectes are observed only about outcomes with no intervention.-9. Intervention 2: 6- Internention group B1,2 : Subjects are treated with 50000IU oral vitD3 weekly fo
Treatment - Drugs
Control group C: Subjectes are observed only about outcomes with no intervention.-9
6- Internention group B1,2 : Subjects are treated with 50000IU oral vitD3 weekly for a total duration of 6 weeks and then termination of intervention(100)
7-Intervention group B2,1 :Subjects(200) are treated with Intramascular administration of 300000 IU vitD3 for 1 dose and after 6 weeks they recive 50000IU oral vitaminD3 monthly until delivey.
8-Intervention group B2,2 :Subjects(200) are treated with Intramascular administration of 300000 IU vitD3 for 1 dose and then termination of intervention(100).
2-Intervention group A1,2:Subjects are treatded with 50000IU oral vitaminD3 weekly for a total duration of 12 weeks and then termination of intervention(100).
3-Intervention groupA2,1: Subjects are treated with Intramascular administration of 300000 IU vitaninD3 each 6 week for 2 doses and then they recive 50000IU oral vitaminD3 monthly until delivery(100)
5- Internention group B1,1 : Subjects are treated with 50000IU oral vitD3 weekly for a total duration of 6 weeks and they recive 50000IU oral vitaminD3 monthly until delivery(100).
4-Intervention groupA2,2: Subjects are treated with Intramascular administration of 300000 IU vitaminD3 each 6 week for 2 doses and then termination of intrevention(100).
1-Intervention group A1 ,1: Subjects are treated with 50000IU oral vitD3 weekly for a total duration of 12 weeks and they recive 50000IU oral vitD3 monthly until delivery(100).
Sponsors
Medical Sciences for Research of Shahid Beheshti Medical university
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Pregnant women Current residence in Masjed Soleyman Gestational age under 14 weeks Maternal age18-40 years Singleton pregnancy
Exclusion criteria
Exclusion criteria: Diabetes Chronic hypertension Thyroid diseases Renal dysfunction Cardiovascular diseases Current use of anticonvulsant drugs Phenytoin Carbamazepine Steroidal drugs Anti cholesterol Digoxin Use of any dietary supplement containing more than 400 IU/day of vitamin D
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abortion. Timepoint: In intervention. Method of measurement: Yes/ No.;Preterm Lobour. Timepoint: In intervention. Method of measurement: Yes/ No.;Gestational Diabetes. Timepoint: In intervention. Method of measurement: Yes/ No.;Preeclampsia. Timepoint: In intervention. Method of measurement: Yes/ No.;Serum 25(OH)D concentration in mother. Timepoint: In intervention. Method of measurement: Ng/ml. | — |
Secondary
| Measure | Time frame |
|---|---|
| Birth weigth. Timepoint: after intervention. Method of measurement: gr.;Head circumference. Timepoint: After intervention. Method of measurement: Cm.;Cord blood 25(OH)D level. Timepoint: After intervention. Method of measurement: Ng/ml.;Birth Lenght. Timepoint: After intervention. Method of measurement: Cm.;Cord blood Calcium. Timepoint: After intervention. Method of measurement: Ng/ml.;Apgar Score 1 minute and 5 minute. Timepoint: After intervention. Method of measurement: Standard Apgar Score.;Fall of umbilical cord time. Timepoint: After intervention. Method of measurement: Day.;Neonatal Ecterus. Timepoint: After intervention. Method of measurement: Mg/dl. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Rostami
School of Nursing and Midwifery Shahid Beheshti Medicl University
Outcome results
None listed